Compounds > metrenperone
Page last updated: 2024-12-06

metrenperone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID72005
CHEMBL ID2104852
SCHEMBL ID2109868
MeSH IDM0135621

Synonyms (33)

Synonym
metrenperone (usan/inn)
D05015
81043-56-3
metrenperone
3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2,7-dimethylpyrido[1,2-a]pyrimidin-4-one
bdbm82382
cas_72005
nsc_72005
r 50970
r-50 970
r-50970
CHEMBL2104852
metrenperonum
metrenperone [usan:inn:ban]
4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-2,7-dimethyl-
unii-w1o4fv809g
metrenperona
metrenperonum [inn-latin]
einecs 279-678-7
metrenperona [inn-spanish]
3-(2-(4-(p-fluorobenzoyl)piperidino)ethyl)-2,7-dimethyl-4h-pyrido(1,2-a)pyrimidin-4-one
3-(2-(4-(4-fluorobenzoyl)-1-piperidyl)ethyl)-2,7-dimethyl-4h-pyrido(1,2-a)pyrimidin-4-one
w1o4fv809g ,
r 50 970
FT-0672391
metrenperone [inn]
metrenperone [usan]
DTXSID20230867
SCHEMBL2109868
3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-2,7-dimethyl-4h-pyrido[1,2-a]pyrimidin-4-one
3-(2-(4-(4-fluorobenzoyl)piperidin-1-yl)ethyl)-2,7-dimethyl-4h-pyrido[1,2-a]pyrimidin-4-one
Q27292195
AKOS040747160

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Metrenperone treatment also allowed better restoration of heart rate, and hence, cardiac output was maintained."( Hemodynamic responses to Pasteurella haemolytica inoculation in calves given type 2 serotonergic antagonist.
Amory, H; Desmecht, D; Lekeux, P; Linden, A, 1996)		1.02

Dosage Studied

ExcerptRelevanceReference
"100 mg kg-1 and with a dosage interval of 12 hours should improve pulmonary function."( Comparison of three metrenperone dosage regimens inhibiting the 5-hydroxytryptamine-induced pulmonary dysfunction in cattle.
Amory, H; Desmecht, DJ; Lekeux, PM; Linden, AS; Rollin, FA, 1993)		0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's9 (81.82)18.2507
2000's0 (0.00)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.67 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		1.9610fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		1.9610aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		1.961011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		1.9810monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
skatole
[no description available]		1.9910methylindolehuman metabolite;
mammalian metabolite
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		1.9810cephalosporinfungal metabolite
enrofloxacin
Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.		1.9810cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
mdl 100907
Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.		2.0510
ceftiofur
ceftiofur: structure in first source		1.9810
piperidines
Piperidines: A family of hexahydropyridines.		3.78110
ConditionIndicatedRelationship StrengthStudiesTrials
Injuries, Tendon
[description not available]		02.0510
Bovine Diseases
[description not available]		02.3820
Acute Hypercapnic Respiratory Failure
[description not available]		01.9810
Symptom Cluster
[description not available]		01.9810
Respiratory Insufficiency
Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)		01.9810
Syndrome
A characteristic symptom complex.		01.9810
Acute Respiratory Distress Syndrome
[description not available]		01.9810
Respiratory Distress Syndrome
A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.		01.9810
Disease, Pulmonary
[description not available]		01.9810
Lung Diseases
Pathological processes involving any part of the LUNG.		01.9810
Pasteurellosis, Pneumonic
Bovine respiratory disease found in animals that have been shipped or exposed to CATTLE recently transported. The major agent responsible for the disease is MANNHEIMIA HAEMOLYTICA and less commonly, PASTEURELLA MULTOCIDA or HAEMOPHILUS SOMNUS. All three agents are normal inhabitants of the bovine nasal pharyngeal mucosa but not the LUNG. They are considered opportunistic pathogens following STRESS, PHYSIOLOGICAL and/or a viral infection. The resulting bacterial fibrinous BRONCHOPNEUMONIA is often fatal.		01.9810
Weight Gain
Increase in BODY WEIGHT over existing weight.		01.9810
Infections, Pasteurella
[description not available]		02.3920
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		01.9910
Pneumonia
Infection of the lung often accompanied by inflammation.		01.9910
Bradyarrhythmia
[description not available]		0210
Blood Pressure, Low
[description not available]		0210
Bradycardia
Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.		0210
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.		0210
Endotoxin Shock
[description not available]		01.9610
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		01.9610
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		01.9610